ClinicalTrials.gg
RecruitingNCT05414032MERIDIANUpdated Oct 5, 2026

Molecular Residual Disease Interception in Locoregionally-Advanced High Risk HPV+ and HPV- HNSCC

A Phase 2 interventional study of AZD2936 in Locoregionally Advanced Head and Neck Squamous Cell Carcinoma (LA-HNSCC), sponsored by University Health Network, Toronto. Recruiting at 1 site in Canada. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-05.

Sponsored by University Health Network, Toronto · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jul 2023; still recruiting 3 years 4 months later.
Updated Oct 5, 2026Study contact changedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
102
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 21 studies in Squamous Cell Carcinoma of Head and Neck by University Health Network, Toronto — 6 open to participants now, 8 under way, none of them phase 3. Squamous Cell Carcinoma of Head and Neck · University Health Network, Toronto.

Planned enrollment
2nd of 17
102 · median 30
Started
2023
with 1 other
Phase 2
4 of 21
3 open now
Registered
16th of 21
by date

Among the 21 studies in Squamous Cell Carcinoma of Head and Neck by University Health Network, Toronto, this one is the 2nd largest by planned enrollment of the 17 interventional ones that give a count, is one of 2 that started in 2023, is one of 4 in phase 2, and was the 16th registered.

Squamous Cell Carcinoma of Head and Neck

2,023 studies on the registry are indexed under Squamous Cell Carcinoma of Head and Neck; 573 are open to participants now.

Browse Squamous Cell Carcinoma of Head and Neck studies →

Open to participants now

6 of the 21 studies in Squamous Cell Carcinoma of Head and Neck by University Health Network, Toronto are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 6 open studies →

Where they have run

Who these studies take

Of the 434 Squamous Cell Carcinoma of Head and Neck studies recruiting now, 310 (71%) set no upper age limit and 87 (20%) stop at 75 or younger; 5 take children under 18; 13 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 21 studies in Squamous Cell Carcinoma of Head and Neck by University Health Network, Toronto, or all of them as a file.
02

Study summary

This is a phase II, open-label study to assess the efficacy of AZD2936 in terms of molecular residual disease (MRD) clearance and treatment outcome in patients with MRD after definitive treatment for high risk locoregionally advanced head and neck squamous cell carcinoma (LA-HNSCC). MRD is defined as ctDNA detection in plasma after definitive treatment. Approximately 100 patients are expected to be enrolled.

Read the detailed description

This is a phase II, open-label study to assess the efficacy of AZD2936 in terms of molecular residual disease (MRD) clearance and treatment outcome in patients with MRD after definitive treatment for high risk locoregionally advanced head and neck squamous cell carcinoma (LA-HNSCC). MRD is defined as ctDNA detection in plasma after definitive treatment. Approximately 100 patients are expected to be enrolled.

The study is divided in 5 parts:

Part A and Part B are common for all patients in the study, which are defined as the periods of definitive treatment and post definitive treatment. Definitive treatment will be either surgery followed by radiation or chemoradiation; definitive radiation or definitive chemoradiation according to standard of care (SOC) in our institution. A baseline ctDNA sample collection and CT staging will be done before treatment. ctDNA analysis will be performed in Part B at approximately week 5, week 10, week 26 and week 52 of this period, and patients will be classified as MRD positive or MRD negative. Patients who receive surgery as part of their treatment, will also get ctDNA analysis post-surgery.

Part C is the interventional part of the study (n=14) for patients with MRD or radiological/clinical progression. Patients will continue treatment until the occurrence of any of these circumstances: after completion of 6 cycles, intolerable toxicity or patient decision. ctDNA analysis will be done at week 10 of Part C.

Part D is the follow up part for patients with MRD or radiological/clinical progression. Two ctDNA samples will be analyzed at week 2 and at week 10 of Part D. Plasma samples will be collected every 6 months for the first 3 years and a final sample will be also collected if the patient has radiological or clinical progression. A CT/MRI scan will be performed at week 2 of Part D and, if clinically needed, according to SOC.

Part E is the observational follow up part for patients without MRD at the completion of part B or with MRD but fail screening to enter Parts C and D. ctDNA samples will be collected at radiological or clinical progression. Additional plasma samples at 6 and 12 months after completion of part B are strongly recommended.

03

Conditions studied

  • Locoregionally Advanced Head and Neck Squamous Cell Carcinoma (LA-HNSCC)
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria for All Parts

  1. Age ≥ 18 years at the time of screening or age of consent according to law.
  2. Written and any locally required authorization (e.g., data privacy) obtained from the subject prior to performing any protocol-related procedures, including screening evaluations.
  3. (ECOG) performance status of 0 or 1.
  4. Weight ≥ 35 kg.
  5. Must have a of at least 12 weeks.
  6. Histological or cytological confirmed LA-HNSCC of the oral cavity, oropharynx, hypopharynx, or larynx. Patients with locoregionally advanced unknown head and neck primary but tumor tested to be p16-positive are eligible.
  7. High-risk HPV negative LA-HNSCC patients (stage III-IVB according to AJCC/UICC 8th Edition) OR high-risk HPV positive LA-HNSCC patients (stage III according to AJCC/UICC 8th Edition).
  8. Archival tumor formalin-fixed, paraffin-embedded (FFPE) specimens for correlative biomarker studies are required (1 H\&E and 10 unstained 5 microns slides). If surgery is going to be performed after signing consent, then tumor FFPE from that surgery is allowed.
  9. Patient is a candidate for definitive treatment: either surgery followed by radiation or chemoradiation, OR definitive radiation, OR definitive chemoradiation.

    Inclusion Criteria for Part C

  10. Objective radiological tumor response according to CT or MRI at 8-12 weeks after definitive therapy (surgery followed by radiation or chemoradiation, OR definite radiation, OR definite chemoradiation)
  11. ECOG performance status of 0 or 1 at randomization.
  12. Tumor must express (CPS ≥1) as determined by the local laboratory using the PD-L1 IHC 22C3 pharmDx assay.
  13. Detection of ctDNA in plasma samples collected in Part B in either:

    1. both samples collected at approximately week 5 (4-6) and at week 10 (8-12) OR
    2. only in the week 10 (8-12) sample NOTE: If ctDNA results at Week 10 are equivocal, a new sample should be collected and analyzed to confirm results within 4 weeks.
  14. Adequate organ and marrow functions as defined in Table 4.Table 4 (4.1.2-2): Criteria for Adequate Organ and Marrow Function

    Parameter Value Hematological ≥ 9 g/dL ≥ 1,500 µ/L count ≥ 100,000 µ/L Hepatic- Total ≤ 1.5 ×

    • 3 × ULN is allowed in the presence of documented Gilbert's syndrome and Aspartate transaminase ≤ 3 × ULN

    Renal Serum creatinine or Calculated Serum creatinine \< 1.5 x ULN or CrCl ≥ 40 mL/minute ULN = upper limit normal. a Hematological criteria cannot be met with ongoing or recent blood transfusions (within 28 days prior to the scheduled first dose of study treatment) or require growth factor support (within 21 days prior to the scheduled first dose of study treatment).

    b As determined by Cockcroft-Gault (using actual body weight) or 24-hour urine creatinine clearance.

  15. ≥ 17.
  16. Females of who are sexually active with a nonsterilized male partner must use at least one highly effective method of (see Section 8.1.1 for definition of females of childbearing potential and for a description of highly effective methods of contraception) from screening to 4 months after the final dose of study treatment. It is strongly recommended for the male partner of a female subject to also use male condom plus spermicide throughout this period. Cessation of contraception after this point should be discussed with a responsible physician. Periodic abstinence, the rhythm method, and the withdrawal method are not acceptable methods of contraception.
  17. Nonsterilized male subjects who are sexually active with a female partner of childbearing potential must use a male condom with spermicide from screening to 4 months after receipt of the final dose of study treatment. Periodic abstinence, the rhythm method, and the withdrawal method are not acceptable methods of contraception. It is strongly recommended for the female partner of a male subject to also use a highly effective method of contraception throughout this period, as described in Section 8.1.2. In addition, male subjects must refrain from sperm donation while on study and for 4 months after the final dose of study treatment.

    Inclusion Criteria for Part E

  18. Objective radiological tumor response according to CT or MRI at 8-12 weeks after definitive therapy (surgery followed by radiation or chemoradiation, OR definitive radiation, OR definitive chemoradiation)
  19. No detection of ctDNA in plasma samples analysed in the week 10 (8-12) sample collected in Part B.

    Exclusion Criteria

    Any of the following would exclude the subject from participation in the study:

  20. Histological or confirmed head and neck cancer of any other primary anatomic location in the head and neck not specified in the inclusion criteria including participants with p16-negative squamous cell carcinoma of unknown primary or non-squamous histologies (eg, nasopharynx, paranasal sinus or salivary gland).
  21. Any unresolved toxicity ≥ Grade 2 from previous anticancer therapy with the exception of alopecia, vitiligo, and the laboratory values defined in the inclusion criteria. Participants with irreversible toxicity not reasonably expected to be exacerbated by treatment with AZD2936 may be included only after consultation with the Principal Investigator.
  22. Evidence of distant in staging.
  23. History of allogeneic organ transplantation.
  24. History of allergic reactions or attributed to compounds of similar chemical or biologic composition to AZD2936 or any of the .
  25. History of active primary immunodeficiency.
  26. Active or prior documented or inflammatory disorders (including inflammatory bowel disease [eg, colitis or Crohn's disease], immune related diverticulitis [prior diverticulitis in the context of diverticulosis is allowed provided is not active], systemic lupus erythematosus, Sarcoidosis syndrome, or Wegener syndrome [granulomatosis with polyangiitis, Graves' disease, rheumatoid arthritis, hypophysitis, uveitis, etc]).

    The following are exceptions to this criterion:

    1. Participants with vitiligo or alopecia
    2. Participants with hypothyroidism (eg, following Hashimoto syndrome) stable on hormone replacement
    3. Any chronic skin condition that does not require systemic therapy. Participants without active disease in the last 5 years may be included but only after consultation with the Principal Investigator
    4. Participants with celiac disease controlled by diet alone
  27. Active infection including tuberculosis (clinical evaluation that includes clinical history, physical examination and radiographic findings, and tuberculosis testing in line with local practice), (known positive HBV surface antigen [HBsAg] result), or (HCV) or acute hepatitis A. Participants with a past or resolved HBV infection (defined as the presence of hepatitis B core antibody [anti-HBc] and absence of HBsAg) are eligible. Also participants who have chronic hepatitis B and are receiving suppressive antiviral therapy are allowed to be enrolled if ALT is normal and viral load is controlled (\<100 U/ml by polymerase chain reaction). These patients must remain on antiviral therapy as per institutional practice during the study treatment and follow up period to ensure adequate viral suppression. Participants positive for HCV antibody are eligible only if polymerase chain reaction is negative for HCV RNA.
  28. Patients with a known history of infection with (positive HIV 1/2 antibodies) are excluded. Testing in patients with no known history or no known risk factors is not required.
  29. Uncontrolled intercurrent illness, including but not limited to, ongoing or active infection, symptomatic congestive heart failure, uncontrolled hypertension, coronary artery disease or history of myocardial infarction in the last 12 months or high risk of uncontrolled arrhythmia, active interstitial lung disease, serious chronic gastrointestinal conditions associated with diarrhea, or psychiatric illness/social situations that would limit compliance with study requirement, substantially increase risk of incurring AEs or compromise the ability of the participant to give written informed consent.
  30. History of another primary except for:

    1. Malignancy treated with curative intent and with no known active disease ≥ 2 years before the first dose of study treatment and of low potential risk for recurrence
    2. Adequately treated non-melanoma skin cancer or lentigo maligna without evidence of disease
    3. Adequately treated carcinoma in situ without evidence of disease
    4. Participants with a history of prostate cancer (tumor/node/metastasis stage) of Stage ≤ T2cN0M0 without biochemical recurrence or progression and who in the opinion of the investigator are not deemed to require active intervention.

    Prior/Concomitant Therapy

  31. Any concurrent anticancer treatment. Concurrent use of hormonal therapy for non-cancer-related conditions (eg, hormone replacement therapy) is allowed.
  32. Prior AZD2936 therapy, anti-PD-1/L1 or TIGIT antibody.
  33. Current or prior use of medication within 14 days before the first dose of study intervention. The following are exceptions to this criterion (see Section 4.7.1

    1. Intranasal, inhaled, topical , or local steroid injections (eg, intra-articular injection)
    2. Systemic corticosteroids at physiologic doses not to exceed 10 mg/day of prednisone or its equivalent
    3. Steroids as premedication for hypersensitivity reactions (eg, CT scan premedication)
  34. Receipt of within 30 days prior to the first dose of study intervention. Note: Participants, if enrolled, should not receive live vaccine whilst receiving study intervention and up to 30 days after the last dose of study intervention. COVID 19 vaccination should not be given for 72 hours prior to administration of the first dose of AZD2936.

    Prior/Concurrent Clinical Study Experience

  35. Participation in another clinical study with an product administered in the last 28 days prior to randomization or concurrent enrollment in another clinical study, unless it is an observational (non-interventional) clinical study or during the follow-up period of an interventional study.

    Other Exclusions

  36. Judgment by the investigator that the participant should not participate in the study if the participant is unlikely to comply with study procedures, restrictions and requirements.
  37. For women only - currently pregnant (confirmed with positive pregnancy test) or breastfeeding.
  38. Females who are pregnant, lactating, or intend to become pregnant during their participation in the study.
  39. Subjects who are involuntarily incarcerated or are unable to willingly provide consent or are unable to comply with the protocol procedures.
Terms in these criteria, in plain language(29)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
102 participants (estimated)

Study arms

  • Experimental
    MRD positive and/or radiological/clinical progression Cohort

    Dose formulation- AZD2936 is supplied as a liquid drug product in a 20R vial containing 750 mg (nominal) of active AZD2936. The solution contains 50 mg/mL AZD2936 in 20 mM L-histidine/L- histidine-hydrochloride, 240 mM sucrose, 0.04% (w/v) poloxamer 188, at pH 6.0. Unit dose strength(s)- 750 mg/vial (50 mg/mL) Dosage levels- 750mg administered Q3W Route of administration- IV infusion over 1 hour

    Biological: AZD2936

  • No intervention
    MRD negative Cohort

    Observation

Interventions

  • BiologicalRilvegostomigStudies of RilvegostomigRilvegostomig pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    AZD2936 is a monovalent, bispecific, humanized, IgG1 triple mutant mAb antibody against human PD 1 and TIGIT. AZD2936 was constructed on the backbone of the DuetMab molecule (Mazor et al., 2015), and its antigen binding fragment portions are comprised of the variable domains of the anti TIGIT COM902 antibody and anti PD 1 LO115 antibody. The IgG1 Fc domain carries the triple mutation (L234F/L235E/P331S) designed to reduce Fc mediated immune effector functions. In the preclinical studies, dual blockade of TIGIT and PD 1 by AZD2936 enhanced human T cell function and promoted antitumor immune responses.

06

What researchers measure

Primary outcomes

  1. Efficacy (in terms of ctDNA clearance) of AZD2936 compared to observation (Standard of Care, SOC) in LA-HNSCC patients who have MRD (MRD+) after definitive treatment.

    Clearance of bespoke ctDNA at different time points (week 2 and week 10 after the end of MRD treatment). ctDNA clearance is defined as no detection of ctDNA in both of these two consecutive determinations.

    Time frame: 3 years

Secondary outcomes

  1. Efficacy (in terms of delaying or preventing radiological recurrence of disease or death) of AZD2936 compared to observation (SOC) in MRD+ LA-HNSCC patients after definitive treatment.

    Disease free survival (DFS) at 12 months.

    Time frame: 3 years

  2. Efficacy (in terms of MRD control) of AZD2936 compared to observation (SOC) in MRD+ LA-HNSCC patients after definitive treatment.

    Time to MRD control failure in MRD+ patients. MRD control failure is defined as two consecutive increases in ctDNA levels (week 2 and week 10 in Part D).

    Time frame: 3 years

  3. Efficacy (in terms of median DFS and OS) of AZD2936 compared to observation (SOC) in MRD+ LA-HNSCC patients after definitive treatment.

    Median DFS and OS in MRD+ patients.

    Time frame: 3 years

  4. Safety and tolerability of AZD2936 in MRD+ LA-HNSCC patients after definitive treatment and randomized to receive this combination.

    * Number and severity of treatment related adverse events according to CTCAE v5.0. * Percentage of participants with AEs, SAEs and rate of AZD2936 discontinuation due to toxicity.

    Time frame: 3 years

Other outcomes

  1. Predictive value (in terms of predicting radiological recurrence of disease or death) of HPV DNA in patients with HPV positive LA-HNSCC treated with AZD2936 compared to observation (SOC).

    • Changes in HPV DNA in MRD+ HPV+ patients treated with AZD2936 or under observation and correlation of such changes with DFS.

    Time frame: 3 years

  2. Predictive value (in terms of predicting radiological recurrence of disease or death) of methylated ctDNA in MRD+ LA-HNSCC patients treated with AZD2936 compared to observation (SOC).

    Changes in methylated ctDNA in MRD+ patients treated with AZD2936 or under observation, and correlation of such changes with bespoke ctDNA and with DFS.

    Time frame: 3 years

  3. Kinetics of bespoke ctDNA and HPV DNA in LA-HNSCC patients after definitive therapy

    Changes in quantitative bespoke ctDNA and HPV DNA measurements before treatment and at W4-6 and W 8-12 (Parts A and B).

    Time frame: 2 years

  4. Kinetics of bespoke ctDNA and HPV DNA in MRD+ LA-HNSCC patients who are treated with AZD2936 compared to observation (SOC).

    Changes in quantitative bespoke ctDNA and HPV DNA measurements during and after treatment/observation (Parts C and D).

    Time frame: 3 years

  5. Correlation between radiological response and changes in quantitative bespoke ctDNA and HPV DNA measurements.

    Correlation between radiological response and changes in quantitative bespoke ctDNA and HPV DNA measurements.

    Time frame: 3 years

  6. To explore the impact of detection of bespoke ctDNA post surgery for patients who underwent definitive surgical resection

    • Compare DFS in patients with detectable ctDNA after surgery versus those patients with no detectable ctDNA.

    Time frame: 3 years

  7. To compare bespoke ctDNA detection (MRD) as a predictive biomarker for increased risk of relapse in high risk-LA HNSCC.

    Compare DFS in the MRD-negative observational cohort with DFS in the MRD+ patients under observation (Arm B in Part C).

    Time frame: 3 years

  8. Health related quality of life at various time points throughout the study using the FACT-ICM and EORTC HN43 tool.

    Overall mean changes in FACT-ICM and EORTC HN43 scores in MRD+ LA-HNSCC patients from baseline (of Part C) and cross sectional comparisons including during and after AZD2936/observation and at progression.

    Time frame: 3 years

  9. Health related quality of life at various time points throughout the study using the FACT-ICM and EORTC HN43 tool.

    Overall mean changes in and EORTC HN43 scores in MRD+ LA-HNSCC patients from baseline (of Part A) and cross sectional comparisons including before, during and after AZD2936/observation and at progression

    Time frame: 3 years

  10. Health related quality of life at various time points throughout the study using the FACT-ICM and EORTC HN43 tool.

    -Overall mean changes in EORTC HN43 scores in MRD-negative LA-HNSCC patients from baseline (part A) and cross sectional comparisons including first year post definitive treatment and at progression.

    Time frame: 3 years

  11. Cost effectiveness of the experimental arm vs observation at various time through the study using the EQ-5D-5L.

    • Utilities

    Time frame: 3 years

  12. Cost effectiveness of the experimental arm vs observation at various time through the study using the EQ-5D-5L.

    Costs per life-year gained

    Time frame: 3 years

  13. Cost effectiveness of the experimental arm vs observation at various time through the study using the EQ-5D-5L.

    Quality adjusted life years (QAYs)

    Time frame: 3 years

  14. Cost effectiveness of the experimental arm vs observation at various time through the study using the EQ-5D-5L.

    • Incremental cost effectiveness ratios (ICERs)

    Time frame: 3 years

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2023 (actual). Primary completion is estimated for Sep 2027, 50 months after the start.

Of 299 non-industry phase 2 interventional studies under Squamous Cell Carcinoma of Head and Neck, half reached primary completion within 56 months of starting (the median), counting those still running; a quarter within 37 and three quarters within 85. This study's planned 50 months is below that.

Counting every sponsor, half of 366 studies reached it within 53 months; a quarter within 35 and three quarters within 82.

How these figures are worked out, and which studies are left out of them.

Registered
May 26, 2022
First posted
Jun 10, 2022
StartActual
Jul 12, 2023
Primary completionEst.
Sep 2027
CompletionEst.
Jul 2028
Last update
Oct 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Contact
Study contact changed: M•••@uhn.ca · •••4501→S•••@uhn.ca; t•••@uhn.ca→P•••@uhn.ca. See the current contact
Oct 5, 2026
Site contacts
Changed at 1 site. See the sites
Show the site
  • Princess Margaret Cancer Centre · Toronto, CanadaContact m•••@uhn.ca→S•••@uhn.ca
Oct 5, 2026
Show all 1 update
  1. Oct 5, 2026
    Contact Study contact changed: M•••@uhn.ca · •••4501→S•••@uhn.ca; t•••@uhn.ca→P•••@uhn.ca. See the current contact
    Site contacts Changed at 1 site. See the sites
    Show the site
    • Princess Margaret Cancer Centre · Toronto, CanadaContact m•••@uhn.ca→S•••@uhn.ca
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05414032
Collaborators
AstraZeneca, NeoGenomics Laboratories, Inc., Personalis Inc.
Responsible party
Sponsor
First posted
Jun 10, 2022
Start date
Jul 12, 2023
Primary completion
Sep 2027 (estimated)
Completion
Jul 2028 (estimated)
Last update
Oct 5, 2026

Study contacts

Lillian Siu, MD
Contact
Phase1Ops@uhn.ca
416-946-4501 ext. 2911
Sawako Elston
Contact
Sawako.Elston@uhn.ca
Lillian Siu, MD
principal investigator · Princess Margaret Cancer Centre

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Rilvegostomig

Start the discussion